These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 24099585)

  • 1. Phase I dose-finding study of cabazitaxel administered weekly in patients with advanced solid tumours.
    Fumoleau P; Trigo JM; Isambert N; Sémiond D; Gupta S; Campone M
    BMC Cancer; 2013 Oct; 13():460. PubMed ID: 24099585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 1/2 dose-finding, safety, and activity study of cabazitaxel in pediatric patients with refractory solid tumors including tumors of the central nervous system.
    Manley PE; Trippett T; Smith AA; Macy ME; Leary SES; Boklan J; Cohen KJ; Goldman S; Kilburn LB; Dhall G; Devin J; Herzog CE; Partap S; Fauchet F; Badreddine E; Bernard JP; Chi SN
    Pediatr Blood Cancer; 2018 Sep; 65(9):e27217. PubMed ID: 29750396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cabazitaxel in patients with advanced solid tumours: results of a Phase I and pharmacokinetic study.
    Diéras V; Lortholary A; Laurence V; Delva R; Girre V; Livartowski A; Assadourian S; Semiond D; Pierga JY
    Eur J Cancer; 2013 Jan; 49(1):25-34. PubMed ID: 22975213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumors.
    Lockhart AC; Sundaram S; Sarantopoulos J; Mita MM; Wang-Gillam A; Moseley JL; Barber SL; Lane AR; Wack C; Kassalow L; Dedieu JF; Mita AC
    Invest New Drugs; 2014 Dec; 32(6):1236-45. PubMed ID: 25117475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone.
    Massard C; Mateo J; Loriot Y; Pezaro C; Albiges L; Mehra N; Varga A; Bianchini D; Ryan CJ; Petrylak DP; Attard G; Shen L; Fizazi K; de Bono J
    Ann Oncol; 2017 Jan; 28(1):90-95. PubMed ID: 28039155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignancies.
    Deeken JF; Slack R; Weiss GJ; Ramanathan RK; Pishvaian MJ; Hwang J; Lewandowski K; Subramaniam D; He AR; Cotarla I; Rahman A; Marshall JL
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):627-33. PubMed ID: 23274395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study.
    Villanueva C; Awada A; Campone M; Machiels JP; Besse T; Magherini E; Dubin F; Semiond D; Pivot X
    Eur J Cancer; 2011 May; 47(7):1037-45. PubMed ID: 21339064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial.
    Corn PG; Heath EI; Zurita A; Ramesh N; Xiao L; Sei E; Li-Ning-Tapia E; Tu SM; Subudhi SK; Wang J; Wang X; Efstathiou E; Thompson TC; Troncoso P; Navin N; Logothetis CJ; Aparicio AM
    Lancet Oncol; 2019 Oct; 20(10):1432-1443. PubMed ID: 31515154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies.
    Advani R; Fisher GA; Lum BL; Jambalos C; Cho CD; Cohen M; Gollerkeri A; Sikic BI
    Clin Cancer Res; 2003 Nov; 9(14):5187-94. PubMed ID: 14613998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A dose escalation study of weekly docetaxel in patients with advanced solid tumors.
    Kouroussis C; Agelaki S; Mavroudis D; Souglakos J; Kakolyris S; Kalbakis K; Vardakis N; Reppa D; Hatzidaki D; Samonis G; Georgoulias V
    Cancer Chemother Pharmacol; 2000; 46(6):488-92. PubMed ID: 11138462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors.
    Marshall J; Chen H; Yang D; Figueira M; Bouker KB; Ling Y; Lippman M; Frankel SR; Hayes DF
    Ann Oncol; 2004 Aug; 15(8):1274-83. PubMed ID: 15277270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study.
    Sarantopoulos J; Mita AC; He A; Wade JL; Hsueh CT; Morris JC; Lockhart AC; Quinn DI; Hwang J; Mier J; Zhang W; Wack C; Yin J; Clot PF; Rixe O
    Cancer Chemother Pharmacol; 2017 Feb; 79(2):339-351. PubMed ID: 28058445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer.
    Chen LT; Liu TW; Wu CW; Chung TR; Shiah HS; Jan CM; Liu JM; Whang-Peng J; Chang JY
    Oncology; 2002; 63(3):239-47. PubMed ID: 12381903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
    Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
    Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weekly docetaxel in pretreated metastatic breast cancer patients: a phase I-II study.
    Nisticò C; Cognetti F; Frontini L; Barni S; Ferretti G; Bria E; Milella M; Garufi C; Cuppone F; Vanni B; Carlini P; Terzoli E
    Oncology; 2005; 68(4-6):356-63. PubMed ID: 16020963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of weekly docetaxel and liposomal doxorubicin in patients with advanced solid tumors.
    Kouroussis Ch; Androulakis N; Vamvakas L; Kalykaki A; Spiridonakou S; Kentepozidis N; Saridaki Z; Xiropoulou E; Georgoulias V
    Oncology; 2005; 69(3):202-7. PubMed ID: 16127289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of continuous infusion 9-aminocamptothecin in patients with advanced solid tumors: 21-day infusion is an active well-tolerated regimen.
    Sewak S; Sorich J; O'Leary J
    Anticancer Drugs; 2006 Jun; 17(5):571-9. PubMed ID: 16702815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of larotaxel administered as a 1-h intravenous infusion every 3 weeks to Japanese patients with advanced solid tumours.
    Yamamoto N; Boku N; Minami H
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):129-36. PubMed ID: 19437020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicentre phase II trial of cabazitaxel in patients with advanced non-small-cell lung cancer progressing after docetaxel-based chemotherapy.
    Kotsakis A; Matikas A; Koinis F; Kentepozidis N; Varthalitis II; Karavassilis V; Samantas E; Katsaounis P; Dermitzaki EK; Hatzidaki D; Mavroudis D; Georgoulias V
    Br J Cancer; 2016 Sep; 115(7):784-8. PubMed ID: 27607471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer.
    Moreno L; Casanova M; Chisholm JC; Berlanga P; Chastagner PB; Baruchel S; Amoroso L; Gallego Melcón S; Gerber NU; Bisogno G; Fagioli F; Geoerger B; Glade Bender JL; Aerts I; Bergeron C; Hingorani P; Elias I; Simcock M; Ferrara S; Le Bruchec Y; Slepetis R; Chen N; Vassal G
    Eur J Cancer; 2018 Sep; 100():27-34. PubMed ID: 29936064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.